Uncertainty and validation of health economic decision models

Health Economics

Volumn 19, Issue 1, 2010, Pages 43-55

  Kim, Lois G ^a   Thompson, Simon G ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Aneurysm screening; Cost effectiveness; Decision modelling; Uncertainty; Validation

Indexed keywords

ABDOMINAL AORTA ANEURYSM; ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH ECONOMICS; HUMAN; PRIORITY JOURNAL; PROBABILITY; RELIABILITY; SCREENING; VALIDATION STUDY;

AORTIC ANEURYSM, ABDOMINAL; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; MARKOV CHAINS; MASS SCREENING; MODELS, ECONOMETRIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; UNCERTAINTY;

EID: 74049135676     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1444     Document Type: Article

References (28)

1. Ades AE, Sutton AJ. 2006. Multiparameter evidence synthesis in epidemiology and medical decision-making: current approaches. Journal of the Royal Statistical Society Series A - General 169: 5-35.
2. Ashton HA, Gao L, Kim LG, Druce PS, Thompson SG, Scott RAP. 2007. 15-year follow-up of a randomised ultrasonographic screening trial for abdominal aortic aneurysms. British Journal of Surgery 94: 696-701.
3. Barton P, Bryan S, Robinson S. 2004. Modelling in the economic evaluation of health care: selecting the appropriate approach. Journal of Health Service Research and Policy 9(2): 110-118.
4. Bojke L, Claxton K, Palmer S, Sculpher M. 2006. Defining and characterising structural uncertainty in decision analytic models. 9. Research Paper, University of York Centre for Health Economics.
5. Briggs A. 2005. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in Health 8: 1-2.
6. Briggs AH, O'Brien BJ, Blackhouse G. 2002. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annual Review of Public Health 23: 377-401.
7. Brown LC, Powell JT. 1999. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small Aneurysm Trial Participants. Annals of Surgery 230: 289-296.
8. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, Vray M. 1997. Modelling in economic evaluation: an unavoidable fact of life. Health Economics 6: 217-227.
9. Eddy D. 1985. Technology assessment: the role of mathematical modelling. In Assessing Medical Technologies, Mosteller F (ed.). National Academy Press: Washington, DC; 144-160.
10. Eddy DM, Schlessinger L. 2003. Validation of the Archimedes diabetes model. Diabetes Care 26: 3102-3110.
11. Gray AM. 2006. Cost-effectiveness analyses alongside randomised clinical trials. Clinical Trials 3: 538-542.
12. Jackson CH, Thompson SG, Sharples LD. 2008. Accounting for uncertainty in health economic decision models using model averaging. Journal of the Royal Statistical Society Series A - General, In press.
13. Karnon J. 2003. Alternative decision modelling techniques for the evaluation of health care technologies. Markov processes versus discrete event simulation. Health Economics 12(10): 837-848.
14. Kim LG, Scott RAP, Ashton HA, Thompson SG. 2007a. A sustained mortality benefit from screening for abdominal aortic aneurysm. Annals of Internal Medicine 146: 699-706.
15. Kim LG, Thompson SG, Briggs AH, Buxton MJ, Campbell HE. 2007b. How cost-effective is screening for abdominal aortic aneurysms? Journal of Medical Screening 14: 46-52.
16. Kim LG, Thompson SG, Marteau TM, Scott RA. 2004. Screening for abdominal aortic aneurysms: the effects of age and social deprivation on screening uptake, prevalence and attendance at follow-up in the MASS trial. Journal of Medical Screening 11: 50-53.
17. Multi-centre Aneurysm Screening Study Group. 2002a. Multicentre Aneurysm Screening Study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial. British Medical Journal 325: 1135-1138.
18. Multi-centre Aneurysm Screening Study Group. 2002b. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 360: 1531-1539.
19. Office of National Statistics. 2004. Mortality Statistics Series DH2 No. 30. Deaths in England and Wales, 2003, Office of National Statistics.
20. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. 2004. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Current Medical Research and Opinion 20(1): S27-S40.
21. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, Woolacoot N, Glanville J. 2004. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technology Assessment 8: iii-xi, 1.
22. Russell LB. 2005. Comparing model structures in cost-effectiveness analysis. Medical Decision Making 25: 485-486.
23. Scott RA, Wilson NM, Ashton HA, Kay DN. 1995. Influence of screening on the incidence of ruptured abdominal aortic aneurysm: 5-year results of a randomized controlled study. British Journal of Surgery 82: 1066-1070.
24. Sculpher MJ, Claxton K, Drummond M, McCabe C. 2006. Whither trial-based economic evaluation for health care decision making? Health Economics 15: 677-687.
25. Sendi PP, Craig BA, Pfluger D, Gafni A, Bucher HC. 1999. Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. Journal of Evaluation in Clinical Practice 5: 283-295.
26. Vardulaki KA, Prevost TC, Walker NM, Day NE, Wilmink AB, Quick CR, Ashton HA, Scott RA. 1998. Growth rates and risk of rupture of abdominal aortic aneurysms. British Journal of Surgery 85: 1674-1680.
27. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR. 2003. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value in Health 6: 9-17.
28. Welsing PM, Severens JL, Hartman M, van Gestel AM, van Riel PL, Laan RF. 2006. The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis. Pharmacoeconomics 24: 1011-1020.